Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC SIAIS100 TFA | C46H51ClF5N9O7S | 25 MG
SIAIS100 TFA is a potent BCR-ABL PROTAC degrader with a DC50 value of 2.7 nM. It is used for research into chronic myeloid leukemia (CML), exhibiting anti-proliferative activity against K562 cells with an IC50 value of 12 nM. This compound degrades BCR-ABL with high ratios at nanomolar concentrations and maintains a durable cellular response after drug removal.
- Potent BCR-ABL PROTAC degrader
- Used for chronic myeloid leukemia (CML) research
- Exhibits anti-proliferative activity against K562 cells
- Induces sustained and robust BCR-ABL degradation
- Degrades G250E/T315I mutation dose-dependently
Medchemexpress LLC Pyridostatin (TFA) | 1472611-44-1 | C33H33F3N8O7 | 5 MG
Pyridostatin (TFA) | 1472611-44-1 | C33H33F3N8O7 | 5 MG
Medchemexpress LLC WAAG-3R TFA | 99.8% | 1644.74 | 1 MG
WAAG-3R TFA is a biologically active peptide. Aggrecanases, which are part of the ADAMTS (A disintegrin and metalloprotease with thrombospondin motif) family of proteases, cleave aggrecan, a main structural component of cartilage. Aggrecanase-1 (ADAMTS-4) is a significant aggrecanase in human osteoarthritic cartilage. This FRET peptide was utilized in an ADAMTS-4 (Aggrecanase-1) and ADAMTS-5 (Aggrecanase-2) assay with Ex/Em = 340/420 nm.
- Biologically active peptide.
- Utilized in an ADAMTS-4 (Aggrecanase-1) and ADAMTS-5 (Aggrecanase-2) assay.
- FRET peptide with Ex/Em = 340/420 nm.
Medchemexpress LLC L-lysine, L-lysyl-L-glutaminyl-L-phenylalanyl- | 99.6% | 891.73 | 25 MG
KQFK TFA is a peptide, the trifluoroacetate salt form of KQFK, and serves as an inactive control for KRFK, a peptide derived from TSP-1. This product is for research use only and has not been fully validated for medical applications.
- Molecular formula: C32H46F9N7O12
- Molecular weight: 891.73
- Purity (LCMS): 99.55%
- Appearance: White to off-white solid
- Storage: Powder at -80°C for 2 years or -20°C for 1 year; in solvent at -80°C for 6 months or -20°C for 1 month (sealed, away from moisture)
Medchemexpress LLC Nangibotide TFA | 2014384-91-7 | 99.4% | 1457.46 | 25 MG
Nangibotide TFA | 2014384-91-7 | 99.4% | 1457.46 | 25 MG
Medchemexpress LLC MS15 TFA | C66H80F3N11O7S | 1 MG
MS15 TFA is a potent and selective PROTAC (proteolysis-targeting chimera) degrader that targets AKT. It effectively inhibits the activity of all three AKT isoforms (AKT1, AKT2, and AKT3) with varying potencies. This compound is suitable for research applications to study AKT's role in cellular processes.
- It is a potent and selective AKT PROTAC degrader.
- It inhibits AKT1 activity with an IC50 of 798 nM.
- It inhibits AKT2 activity with an IC50 of 90 nM.
- It inhibits AKT3 activity with an IC50 of 544 nM.
- It is bioavailable in mice through intraperitoneal administration.
- It is supplied as a solid with a white to yellow appearance.
- It is soluble in DMSO at concentrations of 100 mg/mL or higher.
Medchemexpress LLC Gln-AMS TFA | 99.9% | 588.47 | 100 MG
Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor, specifically inhibiting glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 μM.
- Inhibits glutaminyl-tRNA synthetase (GlnRS)
- Type Ia aminoacyl-tRNA synthetase (AARS) inhibitor
- White to off-white solid
- Purity of 99.85%
- Soluble in DMSO at 100 mg/mL
- Store at -20°C under nitrogen
Medchemexpress LLC QL47B TFA | 96.0% | 992.07 | 1 MG
QL47B TFA is a biotinylated analogue of QL47, functioning as a potent inhibitor of BTK with an IC50 value of 1.3 μM. It has demonstrated anti-tumor activity.
- Potent inhibitor of BTK (IC50 value of 1.3 μM)
- Biotinylated analogue
- Exhibits anti-tumor activity
- Available in various pack sizes
- Purity of 96.03%
Medchemexpress LLC 3x DYKDDDDK Tag (TFA) | 98.17% | 3116.90 | 5 MG
DYKDDDDK peptide (FLAG) is a useful tool for investigating the function and localization of proteins when antibodies are not available. It is often used in a 3X FLAG format for purifying difficult proteins that accumulate in low abundance.
- Useful tool for investigating protein function and localization
- Often used in 3X FLAG format for purifying difficult proteins
- Suitable for proteins that accumulate in low abundance
Medchemexpress LLC Survodutide TFA | 99.4% | 4231.62 (free base) | 25 MG
Survodutide TFA is a potent and selective dual agonist targeting the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R), with EC50s of 0.52 nM and 0.33 nM respectively in CHO-K1 cells. This 29-amino-acid acylated peptide, featuring a C18 fatty acid, demonstrates significant anti-obesity efficacy by enhancing energy expenditure and reducing food intake.
- Potent, selective GCGR/GLP-1R dual agonist
- EC50s of 0.52 nM (GCGR) and 0.33 nM (GLP-1R)
- 29-amino-acid acylated peptide
- Contains a C18 fatty acid
- Demonstrates robust anti-obesity efficacy
- Increases energy expenditure and decreases food intake
- Enhanced proteolytic stability
- Extended terminal half-life
Medchemexpress LLC C(avb6)-DOTA (TFA) | 98.6% | 1546.65 | 5 MG
C(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with a DOTA chelator. The Lu(III) complex of this product has a comparable affinity for αvβ6 integrin (IC50=0.8 nM) and can be used as a tumor diagnostic.
- Conjugate of αvβ6 integrin selective peptide ring
- Modified with DOTA chelator
- Lu(III) complex shows high affinity for αvβ6 integrin (IC50=0.8 nM)
- Applicable in tumor diagnostics
Medchemexpress LLC Vm24-toxin TFA | 1373890-79-9 | 3863.59 | 5 MG
Vm24-toxin is a 36-residue peptide that acts as a potent and selective Kv1.3 blocker with a Kd of approximately 3 pM in lymphocytes. It exhibits over 1500-fold affinity for Kv1.3 compared to other tested potassium channels. This toxin attenuates the CD4+ effector memory T cell response to T cell receptor (TCR) stimulation.
- Potent and selective Kv1.3 blocker
- Exhibits over 1500-fold affinity for Kv1.3
- Attenuates CD4+ effector memory T cell response
Apexbio Technology LLC FSLLRY-NH2 TFA 245329-02-6 (free base) 25mg
FSLLRY-NH2 TFA is a synthetic peptide antagonist targeting protease-activated receptor 2 (PAR-2) It is designed to block PAR-2 activation thereby inhibiting intracellular signaling cascades such as calcium mobilization and MAP kinase activation that underlie inflammatory responses nociceptive transmission and immune modulation FSLLRY-NH2 TFA exerts its biological activity primarily through competitive binding to PAR-2 preventing receptor activation and downstream signaling events Based on these pharmacological properties FSLLRY-NH2 TFA holds research potential in the study of inflammation-associated disorders and pain pathways